http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
抗癌 化學療法을 施行한 末期 胃癌患者 에 對한 抗癌調理方과 AC 2 시럽의 效果에 關한 臨床的 考察
방대건,최서영 대한한방성인병학회 2000 韓方成人病學會誌 Vol.6 No.1
Objectives : This study was performed to evaluate the efficiency of Hangamjori-bang and ACⅡsyrup on the decrease side effects of chemotherapy in Stomach cancer patients. Methods : From September 1999 to June 2000, 9 stomach cancer patients were treated with chemotherapy in other hospital and treated with herb medicine (Hangamjori-bang and AC Ⅱsyrup) in Hana Oriental Hospital. Symptoms of patients were evaluated by symptom numeral scale at ① before chemotherapy ② during chemotherapy ③ treated by Herb medicine for 2 weeks after chemotherapy, and Blood analysis were performed. Results : After chemotherapy, Symptom numeral scale were significantly increased on the nausea/ vomitting and Total point compared to before chemotherapy. After Herb medicine (Hangamjori-bang and AC Ⅱsyrup) treated, symptom numeral scale was significantly decreased on the nausea/vomitting, indigestion, abdominal pain and total point compared to after chemotherapy. After herb medicine treatment, symptom numeral scale was significantly decreased on the abdominal pain compared to before chemotherapy and after chemotherapy. The changes of tumor marker (CA 72-4 and CEA) was not significant between before chemotherapy and chemotherapy + herb medcine combine treatment. In blool analysis blood, liver and kidney toxicity caused by western-oriental combine treatment were not seen. Conclusions : This result revealed that Hangamjori-bang and AC Ⅱsyrup were useful to decrease side effects of chemotherapy and symptoms of stomach cancer patients.
Seo, Dae-Bang,Jeong, Hyun Woo,Kim, Yeon-Ji,Kim, Sukyung,Kim, Jeongkee,Lee, Ji Hae,Joo, Kyungmi,Choi, Jin Kyu,Shin, Song Seok,Lee, Sung-Joon Cambridge University Press 2017 The British journal of nutrition Vol.117 No.2
<B>Abstract</B><P>Hyperlipidaemia is a major cause of atherosclerosis and related CVD and can be prevented with natural substances. Previously, we reported that a novel <I>Bacillus</I>-fermented green tea (FGT) exerts anti-obesity and hypolipidaemic effects. This study further investigated the hypotriglyceridaemic and anti-obesogenic effects of FGT and its underlying mechanisms. FGT effectively inhibited pancreatic lipase activity <I>in vitro</I> (IC50, 0·48 mg/ml) and ameliorated postprandial lipaemia in rats (26 % reduction with 500 mg/kg FGT). In hypertriglyceridaemic hamsters, FGT administration significantly reduced plasma TAG levels. In mice, FGT administration (500 mg/kg) for 2 weeks augmented energy expenditure by 22 % through the induction of plasma serotonin, a neurotransmitter that modulates energy expenditure and mRNA expressions of lipid metabolism genes in peripheral tissues. Analysis of the gut microbiota showed that FGT reduced the proportion of the phylum Firmicutes in hamsters, which could further contribute to its anti-obesity effects. Collectively, these data demonstrate that FGT decreases plasma TAG levels via multiple mechanisms including inhibition of pancreatic lipase, augmentation of energy expenditure, induction of serotonin secretion and alteration of gut microbiota. These results suggest that FGT may be a useful natural agent for preventing hypertriglyceridaemia and obesity.</P>
Seo, Dae-Bang,Jeong, Hyun Woo,Cho, Donghyun,Lee, Bum Jin,Lee, Ji Hae,Choi, Jae Young,Bae, Il-Hong,Lee, Sung-Joon Mary Ann Liebert 2015 Journal of medicinal food Vol.18 No.5
<P>Obesity is caused by an imbalance between caloric intake and energy expenditure and accumulation of excess lipids in adipose tissues. Recent studies have demonstrated that green tea and its processed products (e.g., oolong and black tea) are introduced to exert beneficial effects on lipid metabolism. Here, we propose that fermented green tea (FGT) extract, as a novel processed green tea, exhibits antiobesity effects. FGT reduced body weight gain and fat mass without modifying food intake. mRNA expression levels of lipogenic and inflammatory genes were downregulated in white adipose tissue of FGT-administered mice. FGT treatment alleviated glucose intolerance and fatty liver symptoms, common complications of obesity. Notably, FGT restored the changes in gut microbiota composition (e.g., the Firmicutes/Bacteroidetes and Bacteroides/Prevotella ratios), which is reported to be closely related with the development of obesity and insulin resistance, induced by high-fat diets. Collectively, FGT improves obesity and its associated symptoms and modulates composition of gut microbiota; thus, it could be used as a novel dietary component to control obesity and related symptoms.</P>
Coumestrol Induces Mitochondrial Biogenesis by Activating Sirt1 in Cultured Skeletal Muscle Cells
Seo, Dae-Bang,Jeong, Hyun Woo,Lee, Sang-Jun,Lee, Sung-Joon American Chemical Society 2014 Journal of agricultural and food chemistry Vol.62 No.19
<P>The mitochondrion is a central organelle in cellular energy homeostasis; thus, reduced mitochondrial activity has been associated with aging and metabolic disorders. This paper provides biological evidence that coumestrol, which is a natural isoflavone, activates mitochondrial biogenesis. In cultured myocytes, coumestrol activated the silent information regulator two ortholog 1 (Sirt1) through the elevation of the intracellular NAD<SUP>+</SUP>/NADH ratio. Coumestrol also increased the mitochondrial contents and induced the expression of key proteins in the mitochondrial electron transfer chain in cultured myocytes. A Sirt1 inhibitor and Sirt1-targeting siRNAs abolished the effect of coumestrol on mitochondrial biogenesis. Similar to an increase in mitochondrial content, coumestrol improved myocyte function with increased ATP concentration. Taken together, the data suggest that coumestrol is a novel inducer of mitochondrial biogenesis through the activation of Sirt1.</P><P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/jafcau/2014/jafcau.2014.62.issue-19/jf404882w/production/images/medium/jf-2013-04882w_0007.gif'></P><P><A href='http://pubs.acs.org/doi/suppl/10.1021/jf404882w'>ACS Electronic Supporting Info</A></P>
Bang, Kyong-Won,Seo, Soo-Young,Lee, Jae-Wook,Jang, Pil-Sang,Jung, Min-Ho,Chung, Nack-Gyun,Cho, Bin,Jeong, Dae-Chul,Suh, Byung-Kyu,Kim, Hack-Ki The Korean Pediatric Society 2012 Clinical and Experimental Pediatrics (CEP) Vol.55 No.4
Purpose: Improved survival of patients with childhood acute lymphoblastic leukemia (ALL) has drawn attention to the potential for late consequences of previous treatments among survivors, including metabolic syndrome. In this study, we evaluated changes in 3 parameters, namely, random blood glucose, body mass index (BMI), and Z score for BMI (Z-BMI), in children with ALL during chemotherapy and after completion of treatment. Methods: Patients newly diagnosed with ALL from January, 2005 to December, 2008 at Saint Mary's Hospital, The Catholic University of Korea, who completed treatment with chemotherapy only were included (n=107). Random glucose, BMI, and Z-BMI were recorded at 5 intervals: at diagnosis, before maintenance treatment, at completion of maintenance treatment, and 6 and 12 months after completion of maintenance treatment. Similar analyses were conducted on 2 subcohorts based on ALL risk groups. Results: For random glucose, a paired comparison showed significantly lower levels at 12 months post-treatment compared to those at initial diagnosis ($P$ <0.001) and before maintenance ($P$ <0.001). The Z-BMI score was significantly higher before maintenance than at diagnosis ($P$ <0.001), but decreased significantly at the end of treatment ($P$ <0.001) and remained low at 6 months ($P$ <0.001) and 12 months ($P$ <0.001) post-treatment. Similar results were obtained upon analysis of risk group-based subcohorts. Conclusion: For a cohort of ALL patients treated without allogeneic transplantation or cranial irradiation, decrease in random glucose and Z-BMI after completion of chemotherapy does not indicate future glucose intolerance or obesity.
Dae-Hyuk Heo,Yu Min Kang,송경호,Jun-Won Seo,Jeong-Han Kim,June Young Chun,전강일,강창경,Song Mi Moon,Pyoeng Gyun Choe,Wan Beom Park,Ji Hwan Bang,Eu Suk Kim,Hong Bin Kim,Sang-Won Park,Won Sup Oh,Nam Joong Kim,M 대한의학회 2020 Journal of Korean medical science Vol.35 No.11
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with high mortality in East Asia. This study aimed to develop, for primary care providers, a prediction score using initial symptoms and basic laboratory blood tests to differentiate between SFTS and other endemic zoonoses in Korea. Methods: Patients aged ≥ 18 years diagnosed with endemic zoonoses during a 3-year period (between January 2015 and December 2017) were retrospectively enrolled from 4 tertiary university hospitals. A prediction score was built based on multivariate logistic regression analyses. Results: Of 84 patients, 35 with SFTS and 49 with other endemic zoonoses were enrolled. In multivariate logistic regression analysis, independent predictors of SFTS included neurologic symptoms (odds ratio [OR], 12.915; 95% confidence interval [CI], 2.173–76.747), diarrhea (OR, 10.306; 95% CI, 1.588–66.895), leukopenia (< 4,000/mm3 ) (OR, 19.400; 95% CI, 3.290– 114.408), and normal C-reactive protein (< 0.5 mg/dL) (OR, 24.739; 95% CI, 1.812–337.742). We set up a prediction score by assigning one point to each of these four predictors. A score of ≥ 2 had 82.9% sensitivity (95% CI, 71.7%–87.5%) and 95.9% specificity (95% CI, 88.0%–99.2%). The area under the curve of the clinical prediction score was 0.950 (95% CI, 0.903–0.997). Conclusion: This study finding suggests a simple and useful scoring system to predict SFTS in patients with endemic zoonoses. We expect this strategic approach to facilitate early differentiation of SFTS from other endemic zoonoses, especially by primary care providers, and to improve the clinical outcomes.
Bang, Hyun Seok,Seo, Dae Yun,Chung, Young Min,Kim, Do Hyung,Lee, Sam-Jun,Lee, Sung Ryul,Kwak, Hyo-Bum,Kim, Tae Nyun,Kim, Min,Oh, Kyoung-Mo,Son, Young Jin,Kim, Sanghyun,Han, Jin The Korean Society of Pharmacology 2017 The Korean Journal of Physiology & Pharmacology Vol.21 No.6
Ursolic acid (UA) supplementation was previously shown to improve skeletal muscle function in resistance-trained men. This study aimed to determine, using the same experimental paradigm, whether UA also has beneficial effects on exercise-induced skeletal muscle damage markers including the levels of cortisol, B-type natriuretic peptide (BNP), myoglobin, creatine kinase (CK), creatine kinase-myocardial band (CK-MB), and lactate dehydrogenase (LDH) in resistance-trained men. Sixteen healthy participants were randomly assigned to resistance training (RT) or RT+UA groups (n=8 per group). Participants were trained according to the RT program (60~80% of 1 repetition, 6 times/week), and the UA group was additionally given UA supplementation (450 mg/day) for 8 weeks. Blood samples were obtained before and after intervention, and cortisol, BNP, myoglobin, CK, CK-MB, and LDH levels were analyzed. Subjects who underwent RT alone showed no significant change in body composition and markers of skeletal muscle damage, whereas RT+UA group showed slightly decreased body weight and body fat percentage and slightly increased lean body mass, but without statistical significance. In addition, UA supplementation significantly decreased the BNP, CK, CK-MB, and LDH levels (p<0.05). In conclusion, UA supplementation alleviates increased skeletal muscle damage markers after RT. This finding provides evidence for a potential new therapy for resistance-trained men.